Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.
We utilise our cutting-edge, exclusive workflow to develop focused libraries.
Fig. 1. The sreening workflow of Receptor.AI
Utilising molecular simulations, our approach thoroughly examines a wide array of proteins, tracking their conformational changes individually and within complexes. Ensemble virtual screening enables us to address conformational flexibility, revealing essential binding sites at functional regions and allosteric locations. Our rigorous analysis guarantees that no potential mechanism of action is overlooked, aiming to uncover new therapeutic targets and lead compounds across diverse biological functions.
Our library stands out due to several important features:
partner
Reaxense
upacc
Q9H3R5
UPID:
CENPH_HUMAN
Alternative names:
Interphase centromere complex protein 35
Alternative UPACC:
Q9H3R5; A8K3Y1
Background:
Centromere protein H, also known as Interphase centromere complex protein 35, plays a pivotal role in chromosome segregation during cell division. It is a key component of the CENPA-NAC complex, essential for kinetochore protein assembly, mitotic progression, and accurate chromosome alignment on the metaphase plate.
Therapeutic significance:
Understanding the role of Centromere protein H could open doors to potential therapeutic strategies.